Key Points
- Jeffrey Kunins sold 1,797 shares on Dec. 2 at an average price of $539.23 for about $968,996, trimming his ownership by 2.11% to 83,485 shares valued at roughly $45.0M.
- Axon missed quarterly EPS expectations ($1.17 actual vs. $1.63 expected) but revenue rose 30.6% year-over-year to $710.6M, and analysts hold a consensus "Moderate Buy" with a $814 target.
- The stock opened at $543.55, carries a market cap of ~$42.9B and a P/E of 172, signaling a relatively rich valuation despite the earnings miss.
Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CAO Jennifer Mak sold 74 shares of the business's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $536.75, for a total value of $39,719.50. Following the completion of the sale, the chief accounting officer directly owned 14,408 shares of the company's stock, valued at $7,733,494. This represents a 0.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Axon Enterprise Stock Up 0.4%
AXON opened at $545.50 on Thursday. The firm has a market cap of $43.05 billion, a P/E ratio of 172.63, a price-to-earnings-growth ratio of 122.46 and a beta of 1.40. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. The business has a 50 day moving average price of $645.68 and a 200 day moving average price of $722.81. Axon Enterprise, Inc has a twelve month low of $469.24 and a twelve month high of $885.91.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts' consensus estimates of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The company's revenue for the quarter was up 30.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.45 EPS. Research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.
Institutional Investors Weigh In On Axon Enterprise
Hedge funds have recently made changes to their positions in the company. Stone House Investment Management LLC acquired a new position in shares of Axon Enterprise in the 3rd quarter worth approximately $29,000. New Millennium Group LLC bought a new stake in shares of Axon Enterprise during the third quarter worth $29,000. Hemington Wealth Management increased its stake in shares of Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company's stock valued at $33,000 after buying an additional 17 shares in the last quarter. Whipplewood Advisors LLC raised its holdings in shares of Axon Enterprise by 192.9% in the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company's stock valued at $34,000 after buying an additional 27 shares during the last quarter. Finally, Darwin Wealth Management LLC acquired a new position in Axon Enterprise during the 2nd quarter worth about $37,000. Institutional investors and hedge funds own 79.08% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on AXON shares. Cowen reaffirmed a "buy" rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Needham & Company LLC reissued a "buy" rating and set a $870.00 target price on shares of Axon Enterprise in a research report on Wednesday, September 24th. JMP Securities reiterated a "market outperform" rating and issued a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Bank of America boosted their price objective on Axon Enterprise from $895.00 to $1,000.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Finally, Barclays reduced their target price on Axon Enterprise from $861.00 to $702.00 and set an "overweight" rating for the company in a research report on Thursday, November 6th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $814.00.
View Our Latest Report on AXON
About Axon Enterprise
(
Get Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
